Kymera Therapeutics (NASDAQ:KYMR) Director Sells $7,378,582.58 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth sold 81,866 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $90.13, for a total transaction of $7,378,582.58. Following the transaction, the director directly owned 675,341 shares of the company’s stock, valued at approximately $60,868,484.33. This trade represents a 10.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Bruce Booth also recently made the following trade(s):

• On Friday, December 12th, Bruce Booth sold 678 shares of Kymera Therapeutics stock. The shares were sold at an average price of $91.04, for a total value of $61,725.12.
• On Thursday, December 11th, Bruce Booth sold 6,101 shares of Kymera Therapeutics stock. The shares were sold at an average price of $91.23, for a total value of $556,594.23.
• On Wednesday, December 10th, Bruce Booth sold 229,809 shares of Kymera Therapeutics stock. The stock was sold at an average price of $91.73, for a total value of $21,080,379.57.

Kymera Therapeutics Stock Down 0.0%

NASDAQ KYMR opened at $83.49 on Friday. Kymera Therapeutics, Inc. has a fifty-two week low of $19.44 and a fifty-two week high of $103.00. The business has a fifty day moving average of $78.80 and a 200-day moving average of $66.80. The stock has a market cap of $6.82 billion, a price-to-earnings ratio of -22.69 and a beta of 2.20.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). The company had revenue of $2.87 million for the quarter, compared to analyst estimates of $14.80 million. Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The firm’s revenue was down 60.8% on a year-over-year basis. During the same period in the previous year, the business earned ($0.88) EPS. As a group, analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Trending Headlines about Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: HC Wainwright trimmed near‑term loss forecasts (small EPS improvements across Q1–Q4 2026), kept a “Buy” rating and reiterated a $134 price target — this reinforces constructive analyst sentiment and supports buying interest. Read More.
• Positive Sentiment: UBS and several peers have raised price targets (UBS to $128, Barclays/Oppenheimer/Mizuho also higher), signaling consensus analyst optimism around Kymera’s pipeline progress as a medium‑term catalyst. Read More.
• Positive Sentiment: Another outlet reported a price‑target bump to $100 — additional upward target revisions help underpin sentiment even as valuation remains tied to clinical milestones. Read More.
• Positive Sentiment: Coverage highlights a healthy cash runway (~$1.6B reported) and upcoming program milestones (KT‑579 data in 2H26; KT‑621 Phase 2b readouts in 2027) that are the primary value drivers for this clinical‑stage biotech. Read More.
• Neutral Sentiment: Technical/contextual note — KYMR is trading above its 200‑day moving average with elevated volatility (beta ~2.2); analyst average targets remain well above current levels, which can amplify momentum in either direction. Read More.
• Negative Sentiment: Large director sale: Director Bruce Booth sold 81,866 shares (~$7.38M at ≈$90), a material single‑day disposal that can be perceived as profit‑taking and may cap short‑term upside. Read More.
• Negative Sentiment: Multiple senior insiders (CFO Bruce Jacobs, COO Jeremy Chadwick, Jared Gollob and others) disclosed sales across March 2–4 at roughly $85–$89, each trimming holdings by a few percent — repeated insider selling increases short‑term supply and investor caution. Read More.

Hedge Funds Weigh In On Kymera Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Kymera Therapeutics by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock valued at $849,000 after purchasing an additional 1,833 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Kymera Therapeutics by 340.4% during the first quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock worth $13,972,000 after purchasing an additional 394,562 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Kymera Therapeutics by 121.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock worth $24,535,000 after purchasing an additional 491,737 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Kymera Therapeutics by 506.6% in the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock worth $40,000 after buying an additional 770 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Kymera Therapeutics by 5.2% in the second quarter. Geode Capital Management LLC now owns 1,193,112 shares of the company’s stock worth $52,075,000 after buying an additional 59,347 shares during the period.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on KYMR shares. Wells Fargo & Company raised their price objective on Kymera Therapeutics from $69.00 to $116.00 and gave the stock an “overweight” rating in a report on Tuesday, December 9th. Leerink Partners increased their target price on Kymera Therapeutics from $70.00 to $118.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. Oppenheimer increased their target price on Kymera Therapeutics from $67.00 to $120.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 9th. Bank of America raised their price target on Kymera Therapeutics from $71.00 to $112.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Finally, B. Riley Financial lifted their price target on Kymera Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a report on Monday, December 22nd. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $119.50.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.